2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes

Chern En Chiang*, Kwo Chang Ueng, Ting Hsing Chao, Tsung Hsien Lin, Yih Jer Wu, Kang Ling Wang, Shih Hsien Sung, Hung I. Yeh, Yi Heng Li, Ping Yen Liu, Kuan Cheng Chang, Kou Gi Shyu, Jin Long Huang, Cheng Dao Tsai, Huei Fong Hung, Ming En Liu, Tze Fan Chao, Shu Meng Cheng, Hao Min Cheng, Pao Hsien ChuWei Hsian Yin, Yen Wen Wu, Wen Jone Chen, Wen Ter Lai, Shing Jong Lin, San Jou Yeh, Juey Jen Hwang, Charles Jia Yin Hou

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Type 2 diabetes is a major threat to human health in the 21st century. More than half a billion people may suffer from this pandemic disease in 2030, leading to a huge burden of cardiovascular complications. Recently, 2 novel antidiabetic agents, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, reduced cardiovascular complications in a number of randomized control trials. To integrate new information and to achieve a streamlined process for better patient care, a working group was appointed by the Taiwan Society of Cardiology to formulate a stepwise consensus pathway for these therapies to reduce cardiovascular events in patients with type 2 diabetes. This consensus pathway is complementary to clinical guidelines, acting as a reference to improve patient care.

Original languageEnglish
Pages (from-to)129-146
Number of pages18
JournalJACC: Asia
Volume1
Issue number2
DOIs
StatePublished - Sep 2021

Keywords

  • antidiabetic agents
  • chronic kidney disease
  • heart failure
  • Taiwan Society of Cardiology
  • type 2 diabetes

Fingerprint

Dive into the research topics of '2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes'. Together they form a unique fingerprint.

Cite this